@article{7f7347ce81764daeaa27718f9475756e,
title = "The Ongoing Unmet Needs in Chronic Lymphocytic Leukemia: TP53 Disruption, Richter, and Beyond",
keywords = "BCL-2, BTK, CLL, Double refractory CLL, Richter, TP53, Unmet needs",
author = "Wei Ding",
note = "Funding Information: Research funding for clinical trial: Merck, AbbVie, Octapharma, DTRM, and AstraZeneca. Consultancy: Alexion, BeiGene, Octapharma, Merck, and MEI pharma.",
year = "2021",
month = aug,
doi = "10.1016/j.hoc.2021.04.001",
language = "English (US)",
volume = "35",
pages = "739--759",
journal = "Hematology/Oncology Clinics of North America",
issn = "0889-8588",
publisher = "W.B. Saunders Ltd",
number = "4",
}